Actively Recruiting
Phase 1 Study on How Eloralintide LY3841136 is Processed and Tolerated in Adults with Different Levels of Liver Damage or Healthy Liver Function
Led by Eli Lilly and Company · Updated on 2026-06-04
36
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how the medicine Eloralintide LY3841136 is absorbed and used by the body in people with different levels of liver damage, including those with mild, moderate, or severe hepatic impairment, as well as participants with healthy liver function. This Phase 1 study aims to understand the bodys response to a single dose of Eloralintide and to monitor any side effects in these groups. Participants receive a single subcutaneous dose of Eloralintide and are grouped based on liver function normal hepatic function, mild, moderate, or severe hepatic impairment. The study is open-label and randomized, with all groups receiving the same medication administered by injection under the skin. Each participant stays at the clinical research unit for five nights during the study. The total duration for each participant is about 14 weeks. During this time, researchers will measure the drug concentration in the blood over time to assess pharmacokinetics, focusing on the area under the concentration curve and the maximum drug levels. Participants will undergo medical history reviews, physical exams, and lab tests to monitor liver function and check for side effects. Safety and tolerability are closely observed throughout the study period.
CONDITIONS
Brief Title
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here